

# Phospholipase A2 Receptor Antibodies (PLA2R)

<b>Accreditation Status:</b>	<a href="#">UKAS Schedule of Accreditation</a>								
<b>Date scheme started:</b>	2018								
<b>Clinical Application:</b>	Primary (idiopathic) membranous nephropathy								
<b>Analytes:</b>	PLA2R ( <b>SER/055</b> )								
<b>Units for Reporting:</b>	mg/L								
<b>Samples distributed:</b>	Liquid format. Normal and pathological human serum								
<b>Number of distributions per year:</b>	6								
<b>Number of samples per distribution:</b>	2								
<b>Frequency of Distributions:</b>	Every 2 months as outlined in the <a href="#">Distribution Schedule</a>								
<b>Schedule of Analysis:</b>	<a href="#">Data entry</a> is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics								
<b>Data Analysis:</b>	Qualitative responses are assessed by MI scoring in relation to the designated response								
<b>Performance Scoring:</b>	MI scoring								
<b>Criteria of Performance:</b>	Laboratory performance is classified in terms of OMIS over a running analytical window of 6 distributions (12 months)  The categories of performance are: <table><thead><tr><th></th><th><u>Total MIS</u></th></tr></thead><tbody><tr><td>Good</td><td>zero</td></tr><tr><td>Adequate</td><td>1</td></tr><tr><td>Poor</td><td>&gt;1</td></tr></tbody></table>		<u>Total MIS</u>	Good	zero	Adequate	1	Poor	>1
	<u>Total MIS</u>								
Good	zero								
Adequate	1								
Poor	>1								
<b>Persistent Poor Performance:</b>	Defined as being in the Poor Performance category for two or more successive Distributions.								